The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA® showed highly statistically significant rates of endoscopic remission at one year in the pivotal QUASAR program[1],[2],[3],[4],[5] TREMFYA® is now approved… Read More
Consistent improvement in patient reported outcomes with 10 of 11 evaluable patients in the first four cohorts experiencing a reduction in symptom (SDI1) scores at 12 weeks The fourth cohort showed… Read More
DALLAS, TX – Ryan, a leading global tax services and software provider, is pleased to announce the acquisition of Property Tax Advisors LLC, a national property tax consulting firm located in… Read More
In the last 10 days, WELL has closed the acquisition of 3 primary care clinics in BC and executed definitive agreements to acquire 4 diagnostic imaging clinics in Alberta with… Read More
SILVER SPRING, MD & RESEARCH TRIANGLE PARK, N.C. – United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation (PBC), announced the release of its 2024 Corporate Responsibility and Public Benefit… Read More
